Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

TCR2 Therapeutics Inc. - Common Stock (NQ:TCRR)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	-
Bid (Size)	1.490 (52)
Ask (Size)	1.630 (51)
Prev. Close	1.480
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	39,261,745
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying ↗

May 11, 2023

The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...

Via Benzinga

Recap: TCR2 Therapeutics Q1 Earnings ↗

May 11, 2023

Via Benzinga

Performance

More News

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023

From TCR2 Therapeutics

Via GlobeNewswire

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 08, 2023

From TCR2 Therapeutics

Via GlobeNewswire

What To Know About Jefferies's Downgrade of TCR2 Therapeutics ↗

March 09, 2023

Via Benzinga

4 Analysts Have This to Say About TCR2 Therapeutics ↗

March 09, 2023

Via Benzinga

Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company ↗

March 06, 2023

Via Benzinga

Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying ↗

May 08, 2023

Via Benzinga

TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR

April 26, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2023

From TCR2 Therapeutics

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –

March 30, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023 ↗

March 24, 2023

Via Benzinga

TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023

From TCR2 Therapeutics

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗

March 09, 2023

Via Benzinga

TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR

March 08, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023 ↗

March 08, 2023

Via Benzinga

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason ↗

March 07, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 ↗

March 07, 2023

Via Benzinga

Why Is TCR2 Therapeutics Stock Trading Higher Today? ↗

March 06, 2023

Via Benzinga

Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 06, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 06, 2023

Via Benzinga

TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company

March 06, 2023

Via Spotlight Growth

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today? ↗

March 06, 2023

Via InvestorPlace

TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders

March 06, 2023

From Halper Sadeh LLC

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 06, 2023

Via Benzinga

Frequently Asked Questions

Is TCR2 Therapeutics Inc. - Common Stock publicly traded?

Yes, TCR2 Therapeutics Inc. - Common Stock is publicly traded.

What exchange does TCR2 Therapeutics Inc. - Common Stock trade on?

TCR2 Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for TCR2 Therapeutics Inc. - Common Stock?

The ticker symbol for TCR2 Therapeutics Inc. - Common Stock is TCRR on the Nasdaq Stock Market

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.